BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25011996)

  • 21. Non-conventional Inhibitory CD4
    Zappasodi R; Budhu S; Hellmann MD; Postow MA; Senbabaoglu Y; Manne S; Gasmi B; Liu C; Zhong H; Li Y; Huang AC; Hirschhorn-Cymerman D; Panageas KS; Wherry EJ; Merghoub T; Wolchok JD
    Cancer Cell; 2018 Jun; 33(6):1017-1032.e7. PubMed ID: 29894689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.
    Felcht M; Heck M; Weiss C; Becker JC; Dippel E; Müller CS; Nashan D; Sachse MM; Nicolay JP; Booken N; Goerdt S; Klemke CD
    Br J Dermatol; 2012 Aug; 167(2):348-58. PubMed ID: 22512270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 expression and infiltration by CD4
    Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
    Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating precursor CCR7(lo)PD-1(hi) CXCR5⁺ CD4⁺ T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure.
    He J; Tsai LM; Leong YA; Hu X; Ma CS; Chevalier N; Sun X; Vandenberg K; Rockman S; Ding Y; Zhu L; Wei W; Wang C; Karnowski A; Belz GT; Ghali JR; Cook MC; Riminton DS; Veillette A; Schwartzberg PL; Mackay F; Brink R; Tangye SG; Vinuesa CG; Mackay CR; Li Z; Yu D
    Immunity; 2013 Oct; 39(4):770-81. PubMed ID: 24138884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD4
    Çebi M; Durmus H; Aysal F; Özkan B; Gül GE; Çakar A; Hocaoglu M; Mercan M; Yentür SP; Tütüncü M; Yayla V; Akan O; Dogan Ö; Parman Y; Saruhan-Direskeneli G
    Front Immunol; 2020; 11():809. PubMed ID: 32508812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased CCR7
    Huang YX; Zhao QY; Wu LL; Xie DY; Gao ZL; Deng H
    Can J Gastroenterol Hepatol; 2018; 2018():1020925. PubMed ID: 30402448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human umbilical vein endothelial cells promote the inhibitory activation of CD4(+)CD25(+)Foxp3(+) regulatory T cells via PD-L1.
    Chen WJ; Hu XF; Yan M; Zhang WY; Mao XB; Shu YW
    Atherosclerosis; 2016 Jan; 244():108-12. PubMed ID: 26615520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diminished viral control during simian immunodeficiency virus infection is associated with aberrant PD-1hi CD4 T cell enrichment in the lymphoid follicles of the rectal mucosa.
    Mylvaganam GH; Velu V; Hong JJ; Sadagopal S; Kwa S; Basu R; Lawson B; Villinger F; Amara RR
    J Immunol; 2014 Nov; 193(9):4527-36. PubMed ID: 25246494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival.
    Yang ZZ; Grote DM; Ziesmer SC; Xiu B; Novak AJ; Ansell SM
    Blood Cancer J; 2015 Feb; 5(2):e281. PubMed ID: 25700246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Circulating Follicular Regulatory T-Like Cells May Play a Critical Role in Chronic Hepatitis B Virus Infection and Disease Progression.
    Wu X; Su Z; Cai B; Yan L; Li Y; Feng W; Wang L
    Viral Immunol; 2018 Jun; 31(5):379-388. PubMed ID: 29683413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher infiltration of intratumoral CD25+ FOXP3+ lymphocytes correlates with a favorable prognosis in patients with diffuse large B-cell lymphoma.
    Chang C; Chen YP; Medeiros LJ; Chen TY; Chang KC
    Leuk Lymphoma; 2021 Jan; 62(1):76-85. PubMed ID: 32962457
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway.
    Cha Z; Qian G; Zang Y; Gu H; Huang Y; Zhu L; Li J; Liu Y; Tu X; Song H; Qian B
    Exp Cell Res; 2017 Jan; 350(1):154-160. PubMed ID: 27888017
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
    Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
    Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD1
    Wickenden K; Nawaz N; Mamand S; Kotecha D; Wilson AL; Wagner SD; Ahearne MJ
    Diagn Pathol; 2018 Sep; 13(1):74. PubMed ID: 30219078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
    Rodrigues JM; Nikkarinen A; Hollander P; Weibull CE; Räty R; Kolstad A; Amini RM; Porwit A; Jerkeman M; Ek S; Glimelius I
    Br J Haematol; 2021 May; 193(3):520-531. PubMed ID: 33686666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
    Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
    PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.
    Ghebeh H; Barhoush E; Tulbah A; Elkum N; Al-Tweigeri T; Dermime S
    BMC Cancer; 2008 Feb; 8():57. PubMed ID: 18294387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.